Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLH-JAK: Itacitinib for non-severe adult hemophagocytic lymphohistiocytosis
2024-513173-44-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall response rate at day 15. Started May 2022; status: completed.
02
Drugs
itacitinib
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2024-513173-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513173-44-00.